Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation

28 Mar 2025

Abstract excerpt

The presence of neuronal Lewy bodies mainly composed of SNCA/α-synuclein aggregations is a pathological feature of Parkinson disease (PD), whereas reducing SNCA protein levels may slow the progression of this disease. We hypothesized that compounds enhancing SNCA’s interaction with MAP1LC3/LC3 May increase its macroautophagic/autophagic degradation. Here, we conducted small molecule microarray (SMM)-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40143425
DOI: 10.1080/15548627.2025.2483886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradationPMID 40143425Read ↗

The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagySemantic proximity Read ↗

Treatment with diphenyl–pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell deathSemantic proximity Read ↗

Resveratrol Promotes Autophagy to Improve neuronal Injury in Parkinson’s Disease by Regulating SNHG1/miR-128-3p/SNCA AxisSemantic proximity Read ↗

PLK2 disrupts autophagic flux to promote SNCA/α-synuclein pathologySemantic proximity Read ↗

An mTOR-independent Macroautophagy Activator Ameliorates Tauopathy and Prionopathy Neurodegeneration PhenotypesSemantic proximity Read ↗

LAMP2A as a therapeutic target in Parkinson diseaseSemantic proximity Read ↗

G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndromeSemantic proximity Read ↗

FDA-approved PDE4 inhibitors reduce the dominant toxicity of ALS–FTD-associated <i> CHCHD10 <sup>S59L</sup> </i>Semantic proximity Read ↗

High Content Screening and Proteomic Analysis Identify a Kinase Inhibitor that rescues pathological phenotypes in a Patient-Derived Model of Parkinson’s DiseaseSemantic proximity Read ↗

High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson’s diseaseSemantic proximity Read ↗

N-acetyl-l-leucine lowers pS129-synuclein and improves synaptic function in models of Parkinson’s diseaseSemantic proximity Read ↗

n-Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.